PDCD1 and mismatch repair cancer syndrome 1: Recent studies have demonstrated that various tumors with mismatch repair deficiency (dMMR; glioblastomas and gastrointestinal, endometrial, and prostate tumors) are more responsive to programmed cell death protein 1 (PD1) immune checkpoint inhibitors than MMR-proficient tumors are [15,16,17].